

Meeting Minutes

| | | | |
|---|--|---------------------------|--|
| Institution: | Rocky Mountain Cancer Centers, LLC | | |
| Meeting Date: | November 13, 2025 | | |
| Meeting Time | 11:00 AM Mountain Time | | |
| Meeting Type: | Virtual Platform Teleconference (Remote) Open to the Public | | |
| | Member | Voting Member Type | |
| | Noriea, Nicholas | Yes | Chair: Biosafety Expert/HGT Expert |
| | Ellis, Robert | Yes | Core Member: Biosafety Expert/HGT Expert |
| Members in Attendance: | Rastein, Daniel | Yes | Core Member: Biosafety Expert/HGT Expert |
| | Haltiwanger, Brett | Yes | Local Unaffiliated Member |
| | Greiman, Kevin | Yes | Local Unaffiliated Member |
| | Stensgard, Shelby | No | Site Contact |
| Invited Members Not in Attendance: | None | | |
| Guests: | None | | |
| Staff: | Payne, Kaylie | | |

Call to Order: The IBC Chair called the meeting to order at 11:00 PM. A quorum was present as defined in the Sabai IBC Charter.

Conflicts of Interest: The IBC Chair reminded all members present to identify any conflicts of interest (COI). No COI was declared by any voting member of the IBC for any of the items on the agenda.

Public Comments: No public comments were made prior to or at the meeting.

Review of Prior Business: None

Previous Meeting Minutes: Previous meeting minutes from 12-16-24 were reviewed and approved with no changes requested.

New Business:

| | |
|-----------------|----------------|
| PI: | Cohn, Allen MD |
| Sponsor: | BioNTech SE |

Meeting Minutes

| | |
|--------------------------------|---|
| Protocol: | BNT122-01 A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection. |
| Review Type: | Annual Review |
| NIH Guidelines Section: | III-C-1 |

Trial Summary: BNT122-01 is a Phase II clinical trial sponsored by BioNTech SE designed to assess the safety and potential efficacy of a recombinant personalized cancer vaccine for the treatment of participants with advanced colorectal cancer following surgical resection. The study agent RO7198457 (autogene cevumeran) consists of messenger RNA (mRNA) expressing personalized tumor antigens formulated as a liposome complex for delivery by intravenous injections

Biosafety Containment Level (BSL): [Because the study agent RO7198457 consists of synthetic mRNA incapable of replication and does not encode for known hazardous transgenes (e.g., toxins or oncogenes), BSL1 containment is considered the minimum biocontainment level. The administration of this agent by intravenous infusion in a clinical setting requires compliance with the OSHA Bloodborne Pathogen Standard.

Risk Assessment and Discussion:

- The Committee reviewed the clinical trial Sponsor's study documents and the Sabai-generated comprehensive study-specific Risk Assessment which collectively provided a thorough description of the recombinant or synthetic nucleic acid molecules (investigational product/s) and the proposed clinical research activities involving the IP.
 - In summary, the primary risks in this clinical trial include potential occupational exposure from accidental spills or splashes of the IP during preparation and/or administration procedures and needlesticks due to the use of needles during preparation and/or administration. These potential risks are mitigated through a combination of relevant staff

Meeting Minutes

training, safe clinical practices including Standard Precautions and sharps safety and use of appropriate PPE (as prescribed in the Risk Assessment and documented in the IBC submission package).

- The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the IP will handle the IP or any materials contaminated by the IP.
- The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the IP.
- The Site confirmed that staff members receive Bloodborne Pathogens training.
- Occupational Health Recommendations: None
- The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial, or the proposed mitigation strategies, as detailed in the Risk Assessment.

- The Committee reviewed the Site's facility details, relevant study-specific procedures and practices, the Annual Review Report and other applicable information provided by the Site for the purposes of the IBC review.
 - The Site verified that the information provided by the Chair was accurate.
 - In response to a question from the Committee, the Site confirmed the portable eyewash bottles are checked regularly for expiration.

Motion: A motion of Full Approval for the study at BSL-1 plus Standard Precautions was passed by unanimous vote. There were no votes against and no abstentions.

- Contingencies stated by the Committee: None
- Stipulations stated by the Committee: None

Review of Incidents: Nothing to report.

IBC Training: Nothing to report.

Reminder of IBC Approval Requirements.

Adjournment: The IBC Chair adjourned the meeting at 11:21 AM

Meeting Minutes

Post-Meeting Pre-Approval Note: None